Literature DB >> 1620360

Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy.

S J Bird1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1620360     DOI： 10.1212/wnl.42.7.1422

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  7 in total

Review 1.  Intravenous immunoglobulin therapy in neurological diseases during pregnancy.

Authors:  Isabel Ringel; Uwe K Zettl
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 2.  Neurological paraneoplastic syndromes.

Authors:  J Dalmau; J B Posner
Journal:  Springer Semin Immunopathol       Date:  1996

Review 3.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

Review 4.  Lambert-Eaton myasthenic syndrome.

Authors:  U Seneviratne; R de Silva
Journal:  Postgrad Med J       Date:  1999-09       Impact factor: 2.401

Review 5.  IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.

Authors:  Isabel Illa
Journal:  J Neurol       Date:  2005-05       Impact factor: 4.849

Review 6.  Treatment for Lambert-Eaton myasthenic syndrome.

Authors:  Michael Keogh; Saam Sedehizadeh; Paul Maddison
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

Review 7.  Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.

Authors:  Tyler B Tarr; Peter Wipf; Stephen D Meriney
Journal:  Mol Neurobiol       Date:  2014-09-09       Impact factor: 5.590
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.